Oncolytic Viruses, An Emerging Anti-Cancer Immunotherapy: Current Achievements and Future Directions
DOI:
https://doi.org/10.54097/33r0fz19Keywords:
Oncolytic viruses, glioblastoma, cancer treatment, immunotherapy.Abstract
Oncolytic viruses (OVs) are currently influencing biological cancer therapy. It is a recently created immunotherapy that has been approved to treat cancer and can promote the death of specific cell types to promote antitumor immunological effects. Given the complicated conditions in the tumor micro environment (TME), trials involving the use of OVs demonstrated that OVs could potentially be utilized independently or in combination with other therapies like radiotherapy, chemotherapy, immune checkpoint inhibitors, as well as surgery. While immune suppression against tumors is of critical importance in OV therapy, concurrent antiviral immune responses should also be taken into consideration. Because of this, antiviral immune responses limit OV infections and replication, which also restricts the oncolytic effects of OVs. Recent studies on the operation and mechanics of OVs and how they are employed in clinics has produced results that are encouraging for the future. This review outlined the traits and biological categories of potential OVs, presented the findings of clinical trials, and discussed combinations with other forms of cancer therapy.
Downloads
References
Bray F, Laversanne M. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021, 127(16):3029-30.
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. Ca-a Cancer Journal for Clinicians. 2023, 73(1):17-48.
Shalhout SZ, Miller DM, Emerick KS, Kaufman HL. Therapy with oncolytic viruses: progress and challenges. Nat Rev Clin Oncol. 2023, 20(3):160-77.
Lin D, Shen Y, Liang T. Oncolytic virotherapy: basic principles, recent advances and future directions. Signal Transduct Target Ther. 2023, 8(1):156.
Liang M. Oncorine, the World First Oncolytic Virus Medicine and its Update in China. Curr Cancer Drug Targets. 2018, 18(2):171-6.
Frampton JE. Teserpaturev/G47Δ: First Approval. BioDrugs. 2022, 36(5):667-72.
Allen C, Her S. Radiotherapy for Cancer: Present and Future. Adv Drug Deliv Rev. 2017, 109:1-2.
O'Connor MJ. Targeting the DNA Damage Response in Cancer. Molecular Cell. 2015, 60(4):547-60.
Mody MD, Rocco JW, Yom SS, Haddad RI, Saba NF. Head and neck cancer. The Lancet. 2021, 398(10318):2289-99.
Brown CE, Badie B, Barish ME, Weng LH, Ostberg JR, Chang WC, et al. Bioactivity and Safety of IL13R alpha 2-Redirected Chimeric Antigen Receptor CD8(+) T Cells in Patients with Recurrent Glioblastoma. Clinical Cancer Research. 2015, 21(18):4062-72.
Bartolome RA, Martin-Regalado A, Jaen M, Zannikou M, Zhang P, de los Rios V, et al. Protein Tyrosine Phosphatase-1B Inhibition Disrupts IL13R alpha 2-Promoted Invasion and Metastasis in Cancer Cells. Cancers. 2020, 12(2).
Rong L, Li N, Zhang Z. Emerging therapies for glioblastoma: current state and future directions. J Exp Clin Cancer Res. 2022, 41(1):142.
Saxena M, van der Burg SH, Melief CJM, Bhardwaj N. Therapeutic cancer vaccines. Nat Rev Cancer. 2021, 21(6):360-78.
Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nature reviews Drug discovery. 2015, 14(9):642-62.
Thaker SK, Ch'ng J, Christofk HR. Viral hijacking of cellular metabolism. Bmc Biology. 2019, 17.
Harrington K, Freeman DJ, Kelly B, Harper J, Soria JC. Optimizing oncolytic virotherapy in cancer treatment. Nature Reviews Drug Discovery. 2019, 18(9):689-706.
Gujar S, Pol JG, Kim Y, Lee PW, Kroemer G. Antitumor benefits of antiviral immunity: an underappreciated aspect of oncolytic virotherapies. Trends in immunology. 2018, 39(3):209-21.
Zhou X, Jiang W, Liu Z, Liu S, Liang X. Virus infection and death receptor-mediated apoptosis. Viruses. 2017, 9(11):316.
Liu X, Zhang Z, Ruan J, Pan Y, Magupalli VG, Wu H, et al. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature. 2016, 535(7610):153-8.
Santry LA, van Vloten JP, Knapp JP, Matuszewska K, McAusland TM, Minott JA, et al. Tumour vasculature: Friend or foe of oncolytic viruses? Cytokine & Growth Factor Reviews. 2020, 56:69-82.
Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science. 1991, 252(5007):854-6.
Taguchi S, Fukuhara H, Todo T. Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives. Japanese Journal of Clinical Oncology. 2019, 49(3):201-9.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
